The attractiveness of these NPs for developing a possible PD-modifying therapeutic approach is reinforced by the fact that human recombinant ANP (Carperitide), BNP (Nesiritide, BNP-32), and CNP (Vosiritide) have already entered in clinical trials for the treatment of heart diseases/dysfunctions and hypertension and, de facto, have already passed the toxicological screening for extension of the therapeutic application of these molecules. The gene discussed is NPPA; the disease is Hypertension.